About Dynein axonemal heavy chain 3
Dynein axonemal heavy chain 3 (DNAH3) is a protein
from Homo sapiens identified by UniProt accession
Q8TD57, 4116 residues long.
MolForge cross-references it against 0 known binders and
33 disease associations.
Target properties
| Protein name | Dynein axonemal heavy chain 3 |
|---|
| UniProt accession | Q8TD57 |
|---|
| Gene | DNAH3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 4116 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (33)
Diseases linked to this target (Open Targets).
- spermatogenic failure 18 · score 0.49
- systolic blood pressure · score 0.35
- urate measurement · score 0.34
- diastolic blood pressure · score 0.33
- total blood protein measurement · score 0.32
- cystatin C measurement · score 0.29
- creatinine measurement · score 0.29
- platelet count · score 0.22
- platelet crit · score 0.20
- Intellectual disability · score 0.12
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (4116 residues)
MGATGRLELT LAAPPHPGPA FQRSKARETQ GEEEGSEMQI AKSDSIHHMS HSQGQPELPP LPASANEEPS GLYQTVMSHS FYPPLMQRTS WTLAAPFKEQ HHHRGPSDSI ANNYSLMAQD LKLKDLLKVY QPATISVPRD RTGQGLPSSG NRSSSEPMRK KTKFSSRNKE DSTRIKLAFK TSIFSPMKKE VKTSLTFPGS RPMSPEQQLD VMLQQEMEME SKEKKPSESD LERYYYYLTN GIRKDMIAPE EGEVMVRISK LISNTLLTSP FLEPLMVVLV QEKENDYYCS LMKSIVDYIL MDPMERKRLF IESIPRLFPQ RVIRAPVPWH SVYRSAKKWN EEHLHTVNPM MLRLKELWFA EFRDLRFVRT AEILAGKLPL QPQEFWDVIQ KHCLEAHQTL LNKWIPTCAQ LFTSRKEHWI HFAPKSNYDS SRNIEEYFAS VASFMSLQLR ELVIKSLEDL VSLFMIHKDG NDFKEPYQEM KFFIPQLIMI KLEVSEPIIV FNPSFDGCWE LIRDSFLEII KNSNGIPKLK YIPLKFSFTA AAADRQCVKA AEPGEPSMHA AATAMAELKG YNLLLGTVNA EEKLVSDFLI QTFKVFQKNQ VGPCKYLNVY KKYVDLLDNT AEQNIAAFLK ENHDIDDFVT KINAIKKRRN EIASMNITVP LAMFCLDATA LNHDLCERAQ NLKDHLIQFQ VDVNRDTNTS ICNQYSHIAD KVSEVPANTK ELVSLIEFLK KSSAVTVFKL RRQLRDASER LEFLMDYADL PYQIEDIFDN SRNLLLHKRD QAEMDLIKRC SEFELRLEGY HRELESFRKR EVMTTEEMKH NVEKLNELSK NLNRAFAEFE LINKEEELLE KEKSTYPLLQ AMLKNKVPYE QLWSTAYEFS IKSEEWMNGP LFLLNAEQIA EEIGNMWRTT YKLIKTLSDV PAPRRLAENV KIKIDKFKQY IPILSISCNP GMKDRHWQQI SEIVGYEIKP TETTCLSNML EFGFGKFVEK LEPIGAAASK EYSLEKNLDR MKLDWVNVTF SFVKYRDTDT NILCAIDDIQ MLLDDHVIKT QTMCGSPFIK PIEAECRKWE EKLIRIQDNL DAWLKCQATW LYLEPIFSSE DIIAQMPEEG RKFGIVDSYW KSLMSQAVKD NRILVAADQP RMAEKLQEAN FLLEDIQKGL NDYLEKKRLF FPRFFFLSND ELLEILSETK DPLRVQPHLK KCFEGIAKLE FTDNLEIVGM ISSEKETVPF IQKIYPANAK GMVEKWLQQV EQMMLASMRE VIGLGIEAYV KVPRNHWVLQ WPGQVVICVS SIFWTQEVSQ ALAENTLLDF LKKSNDQIAQ IVQLVRGKLS SGARLTLGAL TVIDVHARDV VAKLSEDRVS DLNDFQWISQ LRYYWVAKDV QVQIITTEAL YGYEYLGNSP RLVITPLTDR CYRTLMGALK LNLGGAPEGP AGTGKTETTK DLAKALAKQC VVFNCSDGLD YKAMGKFFKG LAQAGAWACF DEFNRIEVEV LSVVAQQILS IQQAIIRKLK TFIFEGTELS LNPTCAVFIT MNPGYAGRAE LPDNLKALFR TVAMMVPDYA LIGEISLYSM GFLDSRSLAQ KIVATYRLCS EQLSSQHHYD YGMRAVKSVL TAAGNLKLKY PEENESVLLL RALLDVNLAK FLAQDVPLFQ GIISDLFPGV VLPKPDYEVF LKVLNDNIKK MKLQPVPWFI GKIIQIYEMM LVRHGYMIVG DPMGGKTSAY KVLAAALGDL HAANQMEEFA VEYKIINPKA ITMGQLYGCF DQVSHEWMDG VLANAFREQA SSLSDDRKWI IFDGPVDAIW IENMNTVLDD NKKLCLMSGE IIQMNSKMSL IFEPADLEQA SPATVSRCGM IYMEPHQLGW KPLKDSYMDT LPSSLTKEHK ELVNDMFMWL VQPCLEFGRL HCKFVVQTSP IHLAFSMMRL YSSLLDEIRA VEEEEMELGE GLSSQQIFLW LQGLFLFSLV WTVAGTINAD SRKKFDVFFR NLIMGMDDNH PRPKSVKLTK NNIFPERGSI YDFYFIKQAS GHWETWTQYI TKEEEKVPAG AKVSELIIPT METARQSFFL KTYLDHEIPM LFVGPTGTGK SAITNNFLLH LPKNTYLPNC INFSARTSAN QTQDIIMSKL DRRRKGLFGP PIGKKAVVFV DDLNMPAKEV YGAQPPIELL RQWIDHGYWF DKKDTTRLDI VDMLLVTAMG PPGGGRNDIT GRFTRHLNII SINAFEDDIL TKIFSSIVDW HFGKGFDVMF LRYGKMLVQA TKTIYRDAVE NFLPTPSKSH YVFNLRDFSR VIQGVLLCPH THLQDVEKCI RLWIHEVYRV FYDRLIDKED RQVFFNMVKE TTSNCFKQTI EKVLIHLSPT GKIVDDNIRS LFFGDYFKPE SDQKIYDEIT DLKQLTVVME HYLEEFNNIS KAPMSLVMFR FAIEHISRIC RVLKQDKGHL LLVGIGGSGR QSAAKLSTFM NAYELYQIEI TKNYAGNDWR EDLKKIILQV GVATKSTVFL FADNQIKDES FVEDINMLLN TGDVPNIFPA DEKADIVEKM QTAARTQGEK VEVTPLSMYN FFIERVINKI SFSLAMSPIG DAFRNRLRMF PSLINCCTID WFQSWPTDAL ELVANKFLED VELDDNIRVE VVSMCKYFQE SVKKLSLDYY NKLRRHNYVT PTSYLELILT FKTLLNSKRQ EVAMMRNRYL TGLQKLDFAA SQVAVMQREL TALQPQLILT SEETAKMMVK IEAETREADG KKLLVQADEK EANVAAAIAQ GIKNECEGDL AEAMPALEAA LAALDTLNPA DISLVKSMQN PPGPVKLVME SICIMKGMKP ERKPDPSGSG KMIEDYWGVS KKILGDLKFL ESLKTYDKDN IPPLTMKRIR ERFINHPEFQ PAVIKNVSSA CEGLCKWVRA MEVYDRVAKV VAPKRERLRE AEGKLAAQMQ KLNQKRAELK LVVDRLQALN DDFEEMNTKK KDLEENIEIC SQKLVRAEKL ISGLGGEKDR WTEAARQLGI RYTNLTGDVL LSSGTVAYLG AFTVDYRVQC QNQWLAECKD KVIPGFSDFS LSHTLGDPIK IRAWQIAGLP VDSFSIDNGI IVSNSRRWAL MIDPHGQANK WIKNMEKANK LAVIKFSDSN YMRMLENALQ LGTPVLIENI GEELDASIEP ILLKATFKQQ GVEYMRLGEN IIEYSRDFKL YITTRLRNPH YLPEVAVKVC LLNFMITPLG LQDQLLGIVA AKEKPELEEK KNQLIVESAK NKKHLKEIED KILEVLSMSK GNILEDETAI KVLSSSKVLS EEISEKQKVA SMTETQIDET RMGYKPVAVH SATIFFCISD LANIEPMYQY SLTWFINLYM HSLTHSTKSE ELNLRIKYII DHFTLSIYNN VCRSLFEKDK LLFSLLLTIG IMKQKKEITE EVWYFLLTGG IALDNPYPNP APQWLSEKAW AEIVRASALP KLHGLMEHLE QNLGEWKLIY DSAWPHEEQL PGSWKFSQGL EKMVILRCLR PDKMVPAVRE FIAEHMGKLY IEAPTFDLQG SYNDSSCCAP LIFVLSPSAD PMAGLLKFAD DLGMGGTRTQ TISLGQGQGP IAAKMINNAI KDGTWVVLQN CHLAASWMPT LEKICEEVIV PESTNARFRL WLTSYPSEKF PVSILQNGIK MTNEPPKGLR ANLLRSYLND PISDPVFFQS CAKAVMWQKM LFGLCFFHAV VQERRNFGPL GWNIPYEFNE SDLRISMWQI QMFLNDYKEV PFDALTYLTG ECNYGGRVTD DKDRRLLLSL LSMFYCKEIE EDYYSLAPGD TYYIPPHGSY QSYIDYLRNL PITAHPEVFG LHENADITKD NQETNQLFEG VLLTLPRQSG GSGKSPQEVV EELAQDILSK LPRDFDLEEV MKLYPVVYEE SMNTVLRQEL IRFNRLTKVV RRSLINLGRA IKGQVLMSSE LEEVFNSMLV GKVPAMWAAK SYPSLKPLGG YVADLLARLT FFQEWIDKGP PVVFWISGFY FTQSFLTGVS QNYARKYTIP IDHIGFEFEV TPQETVMENN PEDGAYIKGL FLEGARWDRK TMQIGESLPK ILYDPLPIIW LKPGESAMFL HQDIYVCPVY KTSARRGTLS TTGHSTNYVL SIELPTDMPQ KHWINRGVAS LCQLDN
Explore Dynein axonemal heavy chain 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets